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Protamine Sulfate Use Does Not Lower Hemorrhagic
Complications in Lower Extremity Bypass (LEB)
James T. McPhee, Karen J. Ho, Joseph Lopez, Robert
Glynn, Michael Belkin, Matthew T. Menard. Vascular and
Endovascular Surgery, Brigham and Women’s Hospital,
Boston, MA
Objectives: Protamine Sulfate (PS) use in LEB is
highly variable. We sought to evaluate whether our selec-
tive use of PS was associated with hemorrhagic or throm-
botic complications following LEB.
Methods: All LEB in our institutional registry for occlu-
sive disease from 1/05-7/11were included. 519 LEB under-
went 1:1 propensity score matching to create similar PS and
no-PS cohorts. The primary endpoint was a composite of
hemorrhagic complications (hematoma, re-op for bleeding,
transfusion). 30-day graft patency was a secondary endpoint.
Results: 358 matched bypasses were analyzed: 179 re-
ceived PS and 179 did not. The propensity matched groups
were similar across all assessed variables (Table). By univariate
analysis, the PS and no-PS groups had similar rates of postop
hematoma (5.6% vs 3.3%, P .44), re-exploration for bleed-
ing (1.7% vs 1.1%, P .84), transfusion (20.1% vs 18.4%, P
.79), and composite ”any-bleeding complication” (24.6% vs
20.7%, P  .45). Each group had a similar 30-day primary
patency rate of 96%. By multivariable analysis, PS use did not
reduce hemorrhagic complications (OR0.8;95%CI0.48-1.3;
P  .35) and was not associated with loss of primary patency
(HR 0.72;95% CI 0.49-1.05; P  .1).
Conclusions: This propensity matched analysis dem-
onstrates that while selective use of PS was not protective
against hemorrhagic complications, it appears safe for use
even in grafts at higher risk of thrombosis.
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Predictive Factors of Thirty-Day Unplanned Read-
mission (URA) after Lower Extremity Bypass (LEB)
James T. McPhee1, Neal R. Barshes2, Karen J. Ho1, Arin
Madenci1, Charles K. Ozaki1, Louis L. Nguyen1, Michael
Belkin1. 1Vascular and Endovascular Surgery, Brigham and
Women’s Hospital, Boston, MA; 2Michael E. DeBakey VA
Medical Center, Houston, TX
Objectives: 30-day URA after LEB is large cost-bur-
den and a target for cost containment strategies. We under-
took this study to identify factors associated with URA after
LEB.
Methods: This is a retrospective analysis from a pro-
spective institutional registry. All LEBs for occlusive disease
from 1/95-7/11 were included. The primary endpoint was
30-day URA.
Results: Of 1543 LEBs, 27 patients (1.7%) died in
house and were excluded. Of 1516 remaining LEBs,
84.5% were for CLI and 349 (23.0%) had 30-day URA.
Univariate predictors of URA are shown in the Table. By
multivariable analysis, pre-operative factors predictive of
URA were: Dialysis (OR 1.73, P  .004), Tissue loss
(OR 1.62, P  .0004), and CHF (OR 1.43, P .03).
Postoperative predictors included: SFA inflow source
(OR 1.38, P  .016), wound infection (OR 8.30, P
.0001) in-hospital graft failure (OR 3.20, P .0001)
and MI (OR 1.96, P .04). Conduit type, LOS, and
discharge disposition did not predict URA. URA inde-
pendently predicted loss of assisted primary patency (HR
1.39, P  .01) and long-term limb loss (HR 1.68, P 
.001).
Conclusions: 30-day URA is frequent following LEB
(23%). It is essential to consider risk factors associated with
URA for quality improvement and equitable resource allo-
cation when disease-specific bundling strategies are being
derived.
Table. Baseline characteristics
Unmatched cohort Propensity matched cohort
No protamine(%)
N227(43.7)
Protamine
N292(56.3) P value
No Protamine(%)
N179(50)
Protamine(%)
N179(50) P
Mean age [StdDev] 68.5 [11.4] 69.4 [11.9] .29 69.1 [11.2] 69.0 [12.4] .74
White race 171 (75.3) 240 (82.2) .06 140 (78.2) 144 (80.4) .7
Diabetes mellitus 129 (56.8) 140 (47.9) .05 95 (53.1) 92 (51.4) .83
Critical limb ischemia indication 183 (80.6) 230 (78.8) .66 141 (78.8) 137 (76.5) .7
Preoperative Coumadin 40 (17.6) 72 (24.7) .07 38 (21.2) 40 (22.3) .9
Infrapopliteal target vessel 131 (57.7) 133 (45.5) .006 93 (51.9) 93 (51.9) .99
Any completion study 191 (84.1) 209 (71.6) .0007 149 (83.2) 147 (82.1) .89
”Good” runoff (2-3 vessel) 86 (37.9) 140 (47.9) .03 75 (41.9) 76 (42.5) .99
Prosthetic conduit 46 (20.3) 96 (32.9) .001 43 (24.0) 42 (23.5) .99
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Table. Univariate predictors of unplanned readmission
No unplanned
readmission (%)
N1157(77.0)
Unplanned
readmission(%)
N349(23.0) P value
Mean age [StdDev] 68.4 [11.2] 69.8[11.6] .02
Diabetes mellitus 614 (52.6) 210 (60.2) .014
Dialysis dependence 103 (6.6) 54 (15.5) .006
Congestive heart failure 179 (15.3) 76 (21.8) .006
Tissue loss indication 575 (49.3) 223 (63.9) .0001
SFA inflow 218 (18.7) 88 (25.2) .01
Mean LOS [StdDev] 10.6 [9.7] 12.2 [8.4] .0001
Discharge to nursing facility 570 (48.9) 211 (60.5) .0001
In-hospital wound infection 34 (2.9) 66 (18.9) .0001
Postoperative MI 28 (2.4) 19 (5.4) .007
In-hospital graft failure 46 (3.9) 36 (10.3) .0001
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Surgical Treatment of Popliteal Aneurysms Using a
Posterior Approach: Thirteen Years’ Follow-up
Daniela Mazzaccaro1, Michele Carmo1, Giovanni Grava1,
Alberto M. Settembrini1, Raffaello Dallatana1, Iacopo Bar-
betta1, Piergiorgio Settembrini2. 1Division of Vascular Sur-
gery S.Carlo Borromeo Hospital, Milan, Italy; 2Università
degli Studi di Milano, Milan, Italy
Objectives: Long term results of posterior approach
(PA) for the treatment of popliteal artery aneurysms are
lacking in the literature.
We compared our results with this access with those
from a standard medial approach over a 13-years period.
Methods: Clinical data of all patients treated for a
popliteal aneurysm between 2/1998 and 10/2011 were
retrospectively reviewed and outcomes analyzed: Kaplan-
Meier method with log-rank, chi2 and Wilcoxon test were
employed for analysis.
Results: A total of 78 aneurysms were treated in 66
patients (65 men). Mean age was 68 years (range 48-96
years). Thirty-six aneurysms were asymptomatic (46%).
Mean sac diameter was 2.91 cm. A PA was used in 43
cases (55%) and a medial approach (MA) in 35. All PA
consisted in aneurysmectomy with an interposition graft
with end to end anastomoses; among MA 25 interposition
grafts and 10 bypass were perfomed. A PTFE graft was used
mostly (57 cases). The two groups differed for age only
(median 65,4 for PA vs 72,9 for MA P .01). Five patients
had an early thrombosis and required a Fogarty thrombec-
tomy (2 PA and 3MA, all PTFE grafts).Mortality rate at 30
days was 0%. One patient suffered a peroneal nerve lesion
(permanent) and another one a major wound necrosis with
tissue loss (both PA). There were no early amputations.
Median follow-up was 58,8 months (range 5 days-1667
months). Nine patients died during follow-up for unrelated
causes. The 5-year primary and secondary patency rates
were 58, 9%8, 7% and 96, 4%3, 5% respectively for PA,
and 67, 4%10, 4% and 81, 3%8, 9% respectively for MA
(P  .41 for primary patency rate and 0.28 for secondary
patency rate). Limb salvage was 100% and 93, 3%6, 4% at
5 and 10 years respectively for PA and 91, 5%5, 6% at
both time points for MA (P  .3).
Conclusions: PA in our experience was burdened by a
few more early complications compared to MA. However
in the long term it provided results which compare favour-
ably to MA.
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The Use of Reentry Devices Improves the Technical
Success, Safety, and Patency of Recanalization of
Chronic Total Occlusions of the Iliac Arteries
Sadaf S. Ahanchi, Brian Chen, Samuel Steerman, Richard
Redlinger, Jean M. Panneton. Department of Surgery Di-
vision of Vascular Surgery, Eastern Virginia Medical
School, Norfolk, VA
Objectives:Our aimwas to analyze the effect of reentry
device use on iliac artery chronic total occlusion (CTO)
recanalization outcomes.
Methods:A retrospective review of patients with iliac
artery CTO treated with subintimal angioplasty (SIA)
from 2006 to 2011 was completed. We then compared
the outcomes of two groups: those procedures com-
pleted with versus those procedures completed without a
reentry device using SPSS software (IBM, Armonk, New
York).
Results:Of the 121 iliac artery CTOs that underwent
SIA, 32 cases used a reentry device while 89 did not. For
the entire cohort, the mean age was 65, male 45%,
hypertension 76%, hyperlipidemia 71%, diabetes 36%,
and CAD 56%. Indications for the procedure included
claudication (60%) and critical limb ischemia (40%). The
clinical profile and indications for intervention were not
statistically different for the 2 groups. Combining TASC
C&D lesions, the reentry device group had a trend
toward a higher percentage of more advanced lesions
compared to the non reentry device group (82% versus
66% P  .07). Yet despite the more advanced lesions, the
technical success rate was higher in the reentry device
group (100% versus 77% P  .002). Combined major
complication rate, retrograde aortic dissection, and 30-
day mortality rate of the reentry group was also reduced
(0% versus 10% P  .04). Lastly, the 1, 2 and 3 years
primary and secondary patency rates, especially with long
term follow up, appear to be improved with the use of
reentry devices; primary patency at 1, 2, and 3 years for
the reentry device group versus the non reentry device
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